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P53 and Cancer-Associated Sialylated Glycans Are
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Abstract
Background: Bladder cancer is a significant health problem in rural areas of Africa and the Middle East where Schistosoma
haematobium is prevalent, supporting an association between malignant transformation and infection by this blood fluke.
Nevertheless, the molecular mechanisms linking these events are poorly understood. Bladder cancers in infected
populations are generally diagnosed at a late stage since there is a lack of non-invasive diagnostic tools, hence enforcing
the need for early carcinogenesis markers.
Methodology/Principal Findings: Forty-three formalin-fixed paraffin-embedded bladder biopsies of S. haematobiuminfected patients, consisting of bladder tumours, tumour adjacent mucosa and pre-malignant/malignant urothelial lesions,
were screened for bladder cancer biomarkers. These included the oncoprotein p53, the tumour proliferation rate (Ki-67.
17%), cell-surface cancer-associated glycan sialyl-Tn (sTn) and sialyl-Lewisa/x (sLea/sLex), involved in immune escape and
metastasis. Bladder tumours of non-S. haematobium etiology and normal urothelium were used as controls. S.
haematobium-associated benign/pre-malignant lesions present alterations in p53 and sLex that were also found in bladder
tumors. Similar results were observed in non-S. haematobium associated tumours, irrespectively of their histological nature,
denoting some common molecular pathways. In addition, most benign/pre-malignant lesions also expressed sLea. However,
proliferative phenotypes were more prevalent in lesions adjacent to bladder tumors while sLea was characteristic of sole
benign/pre-malignant lesions, suggesting it may be a biomarker of early carcionogenesis associated with the parasite. A
correlation was observed between the frequency of the biomarkers in the tumor and adjacent mucosa, with the exception
of Ki-67. Most S. haematobium eggs embedded in the urothelium were also positive for sLea and sLex. Reinforcing the
pathologic nature of the studied biomarkers, none was observed in the healthy urothelium.
Conclusion/Significance: This preliminary study suggests that p53 and sialylated glycans are surrogate biomarkers of
bladder cancerization associated with S. haematobium, highlighting a missing link between infection and cancer
development. Eggs of S. haematobium express sLea and sLex antigens in mimicry of human leukocytes glycosylation, which
may play a role in the colonization and disease dissemination. These observations may help the early identification of
infected patients at a higher risk of developing bladder cancer and guide the future development of non-invasive diagnostic
tests.
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has been suggested to depend on the intensity (worm burden and
tissue egg burden) and duration of infection [16,17]. However,
despite the epidemiological data from case control studies and the
geographical overlap between bladder cancer development and
regions endemic for urogenital schistosomiasis [8,18], few experimental evidences support this association. Nonetheless, Botelho and
coworkers demonstrated recently that the exposure to soluble
antigen extracts of mixed sex adult S. haematobium worms and eggs
promote the tumourogenic potential of urothelial cells in vitro and
in vivo [8,19,20], and Zhong and colleagues have reported
hypermethylation of several genes including RASSF1A and TIMP3
detected in urine sediments of Ghanaians with bladder pathology
associated with infection with S. haematobium [21].Further understanding of the pathobiological features underlying the association
between S. haematobium and bladder cancer development are
needed to support these observations. The identification of the
molecular events underlying early urothelial carcinogenesis in the
bladder is also warranted. This is a particular critical matter since
early symptoms of schistosomiasis, which include urinary pain and
hematuria, are common to those of bladder cancer. As such, they are
often neglected by local communities in developing countries, where
medical assistance is scarce. Therefore, bladder tumours are often
diagnosed at a late stage, which is associated with decreased overall
survival. The identification of biomarkers may help to control S.
haematobium-associated bladder cancer in these populations.
This research is based on establishing common molecular
alterations among schistosoma-associated tumours and benign/
pre-malignant lesions found either in tumor-adjacent mucosa or in
apparently normal urothelia of cases without tumors. These lesions
were screened for oncoprotein p53 that is associated with both
aggressive urothelial [22–24] and squamous cell bladder carcinomas [25]. The proliferation rate, given by the overexpression of
nuclear protein Ki-67, and considered a prognostic marker of
tumor recurrence and progression in non-muscle invasive
urothelial carcinoma [26–28], was also evaluated. Particular
attention was further devoted to the characterization of alterations
in membrane-bound glycans that accompanied malignant transformations and favor cell-to-cell detachment, migration, immune
evasion and metastization [29]. This includes the sialylated
antigens sialyl-Tn (sTn; CA72-4) [30,31], sialyl-Lea (sLea, CA199) [32–34] and sialyl-Lex (sLex) [35,36] that have been observed in
bladder cancer. Cancer-associated glycans can also be found in
secreted proteins often shed into the bloodstream and urine,
offering potential for non-invasive diagnosis [34,36–38].

Author Summary
Epidemiological studies associate infection with S. haematobium, an endemic parasitic flatworm in Africa and the
Middle East, with the development of bladder cancer.
Nevertheless, little molecular evidence exists supporting
this association. This work draws attention to the common
molecular pathways underlying these two events, highlighting a potentially unreported link between infection
and cancer development. It has been demonstrated that a
panel of biomarkers commonly associated with aggressive
forms of bladder cancer is also present in non-malignant
tissues infected with the parasite. This may offer a means
of early identification of people with this parasitic infection
who are at risk of developing of bladder cancer, and may
guide the establishment of non-invasive diagnostic tests.
Furthermore, we observed that parasite eggs mimic the
molecular nature of human cells, providing a possible
mechanism of immune escape and persistent infection.
Such knowledge is considered pivotal to develop novel
therapeutic strategies.

Introduction
Schistosoma haematobium, a parasitic flatworm infecting millions
of people in Angola and other countries of Africa and Middle East,
is responsible for the development of urinary schistosomiasis, a
neglected tropical disease [1,2]. The World Health Organization
estimates that 500 to 600 million people residing in rural
agricultural and periurban areas are at risk of infection and over
200 million people are currently infected, 10% of which will
experience sever health complications; [3,4].
The parasite has a complex life cycle consisting of two phases,
one inside the human body (the definitive host) and another inside
a snail of the genus Bulinus [5]. Free-swimming cercariae
penetrate human skin when in contact with contaminated water,
enter the blood stream and travel to the liver to mature into adult
flukes. After a period of about three weeks the young flukes
migrate to the plexuses around the urinary bladder to copulate.
The eggs released by female flukes traverse the wall of the bladder
causing haematuria, fibrosis and ultimately the calcification of the
tissue; they are then excreted through urine [6,7]. However, some
eggs become embedded in the bladder mucosa further contributing to chronic inflammation and granuloma formation [6,7]. The
eruption of the eggs through the mucosa stimulates not only the
establishment of chronic inflammations but also promotes the
development of benign/pre-malignant bladder lesions such as
urothelial hyperplasia and dysplasia that may be precursors of
bladder cancer [8–10]. When contaminated urine comes in
contact with fresh watercourses (e.g. rivers), the eggs hatch,
releasing free-swimming miracidia that infect the intermediate
snail host. After a maturation period new cercariae are formed and
released into the environment, assuring the perpetuation of
infection and transmission of the disease [5].
The World Health Organization (WHO) International Agency
for Cancer classifies S. haematobium as a Group 1 biological
carcinogen, a definitive cause of cancer [11]. Epidemiological
findings reveal a positive relationship between S. haematobium
infection and the development of squamous cell carcinoma of the
bladder, a type of bladder cancer rarely observed in western
patients but prevalent in Africa and Middle East [12–14]. It has
been observed that patients infected with the parasite have a
higher risk of developing bladder cancer earlier in life than
uninfected people [13,15]. The probability of developing cancer
PLOS Neglected Tropical Diseases | www.plosntds.org

Materials and Methods
Ethics Statement
All procedures were performed after patient’s written informed
consent and parental consent in the cases of children and
approved by the Ethics Committee of Agostinho Neto University,
Luanda, Angola and the Portuguese Institute For Oncology of
Porto, Portugal (IPO-Porto). Clinico-pathological information was
obtained from patients’ clinical records and this information was
anonymized.

Cases
This study includes 43 Angolan patients (30.2% male and
69.8% female) diagnosed as positive for S. haematobium infection
in Sagrada Esperança Clinic (Luanda, Angola) and Hospital
Américo Boavida (Luanda, Angola). The median age of the
patients was 33.5 years (12–82 years) and, even though the
majority resided in the rural areas around Luanda, they were born
and had resided in provinces where S. haematobium is endemic.
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Table 1. Pathological characterization of the samples.

With Tumour (n = 19)

Benign/Pre-malignant lesions

No tumour (n = 24)

P

PTLMP

UC

SCC

Chronic Inflammation

6

1

-

4

-

1

Urothelial Hyperplasia

8

-

2

-

2

1

Epidermoid Metaplasia

7

-

-

-

5

2

Displasia

3

-

-

-

-

-

UC+SCC

P: papilloma; PTLMP: papillary tumour of low malignant potential; UC: urothelial tumour; SCC: squamous cell carcinomas; UC+SCC: urothelial cancer and squamous cell
carcinoma.
doi:10.1371/journal.pntd.0003329.t001

All patients presented irregularities of inner surface of bladder wall
found by ultrasound scan and some of them showed a localized
thickening of bladder wall protruding into the lumen. Therefore,
the patients underwent cystoscopy and biopsy of the visualized
mass and corresponding adjacent mucosa. The apparently normal
urothelium of cases without noticeable tumour mass were also
subjected to random biopsies. All biopsies of apparently normal
urothelium and tumour-adjacent mucosa presented benign/premalignant lesions (chronic inflammation, urothelial hyperplasia,
epidermoid metaplasia or dysplasia). Malignant lesions included
papilloma (P), papillary urothelial neoplasm of low malignant
potential (PUNLMP) and high-grade urothelial cell carcinoma
(UCC), squamous cell carcinomas (SCC) or both (UCC+SCC) as
summarized in Table 1. No differences were observed in age and
sex distribution among the lesions/tumours. S. haematobium eggs
were evident in the bladder of 27 (62.8%) cases, from these 7
(26%) presented tumours.
This study also includes a retrospective series of 22 nonSchistosoma haematobium infected patients diagnosed with urothelial cell carcinoma (10 low-grade tumours; 12 high-grade tumours,
5 presenting muscle invasion) and 4 squamous cell carcinomas
presenting invasion of the muscularis propria, that have been
previously characterized in relation to Ki-67 and sTn expressions
by Ferreira et al. [31]. The patients (48.3% male and 51.7%
female), mean age 69 years (45-89 years), underwent transurethral
resection of the tumour in the Portuguese Institute for Oncology of
Porto (IPO-Porto, Portugal), between July 2011 and May 2012.
None had received prior adjuvant therapy. Six normal urothelium
tissues of necropsied male individuals without bladder cancer
history, within the same mean of age range, were also included.
Formalin fixed paraffin embedded biopsies and tumour sections
stained with hematoxylin and eosin were examined and classified
by an experienced pathologist under light microscopy, with
reference to the WHO’s 2004 grading criteria [39].

followed by incubation with 3,3-diaminobenzidine tetrahydrochloride (Impact Dab, Vector). Finally, the slides were
counterstained with haematoxylin for 1 min. Colon carcinoma,
tonsil and intestinal metaplasia tissue sections were tested in
parallel as positive controls for, p53, Ki-67 and sialylated glycans,
respectively. Negative control sections were included, involving
sections probed with BSA (5% in PBS) devoid of primary
antibody. The tissues were also treated with a neuraminidase
from Clostridium perfringens (Sigma-Aldrich) to remove the sialic
acid from the glycans and screened thereafter for sTn, sLea, and
sLex, as described by Ferreira et al. [31].
A semi-quantitative approach was established to score the
immunohistochemical labeling based on the intensity of staining
and the percentage of cells that stained positively. The
immunoexpression was assessed blindly by two independent
observers and validated by an experienced pathologist. Whenever
there was a disagreement, the slides were reviewed, and consensus
was reached. Tumours were classified as p53 positive whenever
expression was higher than 5% of the tissue section, as proliferative
whenever Ki-67 expression was higher than 17%, as described by
Santos et al. [26], and sTn, sLea and sLex were considered positive
whenever the percentage of staining was $5% of the tissue
sections [31,32,35].

Immunohistochemistry

Bladder tumours associated with S. haematobium infection were
screened for the accumulation of p53, proliferation rate (Ki-67.
17%) and cancer-associated sialylated glycans sTn, sLea and sLex
(Fig. 1). We could observe that all the biomarkers were expressed
throughout the different layers of the urothelium in benign/premalignant lesions and also homogeneously expressed in the
tumours, irrespectively of their histological classification. As
presented in Table 2, the majority of the bladder tumors exhibited
p53 alterations (84%) and sLex overexpression (74%). Similar
percentages of p53 and sLex could also be observed in bladder
tumour sections from patients non-infected with Schistosoma
haematobium, irrespectively of their histological natures. Conversely, non-proliferative phenotypes predominated among low
malignant lesions (papilloma and PUNLMP; 100% of the cases)

Statistics
Statistical data analysis was performed using the IBM Statistical
Package for Social Sciences—SPSS for Windows (version 20.0).
Chi-square analysis was used to compare categorical variables.
Correlation between cancer associated markers expression in premalignant lesions and concomitant tumours whenever present was
performed using Pearson correlation test. A P value of #0.05 was
considered to be statistically significant.

Results

Formalin-fixed, paraffin-embedded (FFPE) tissue sections were
screened for p53 accumulation, proliferation (Ki-67), and cancerassociated glycans sTn, sLea, and sLex by immunohistochemistry
by the streptavidin/biotin peroxidase method using mouse
monoclonal antibodies. The p53 protein was determined with
clone DO-7 (Dako), Ki-67 with clone MIB-1 (Dako), sTn with
clone TKH2 [31], sLea with clone (Abcam) and sLex with clone
(Abcam). Briefly, 3 mm sections were deparaffinized with xylene,
rehydrated with graded ethanol series, microwaved for 15 min in
boiling citrate buffer (10 mM citric acid, 0.05% Tween 20,
pH 6.0), and exposed to 3% hydrogen peroxide in methanol for
20 min. After blockage with BSA (5% in PBS), the antigens were
identified with UltraVision Detection System (Thermo Scientific)
PLOS Neglected Tropical Diseases | www.plosntds.org
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Fig. 1. Expression of cancer-associated biomarkers p53, Ki-67, sTn, sLea and sLex in bladder benign/pre-malignant lesions. A)
Chronic inflammation; B) SCC; C) Chronic inflammation; D) SCC; E) Urothelial hyperplasia; F) Urothelial carcinoma; G) Dysplasia; H) SCC; I) Dysplasia; J)
Urothelial carcinoma.
doi:10.1371/journal.pntd.0003329.g001
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Table 2. Cancer associated markers expression in Schistosoma haematobium-associated bladder tumours.

Papilloma

PUNLMP

UCC

SCC

UCC+SCC

Total

n (%)

n (%)

n (%)

n(%)

n(%)

n (%)

Negative

0 (0.0)

0 (0.0)

0 (0.0)

2 (28.6)

1 (25.0)

3 (15.8)

Positive (altered)

1 (100.0)

2 (100.0)

5 (100.0)

5 (71.4)

3 (75.0)

16 (84.2)

Non proliferative

1 (100.0)

2 (100.0)

2 (40.0)

3 (42.9)

2 (50.0)

10 (52.6)

Proliferative (.17%)

0 (0.0)

0 (0.0)

3 (60.0)

4 (57.1)

2 (50.0)

9 (47.4)

Negative

1 (100.0)

1 (50.0)

5 (100.0)

4 (57.1)

1 (25.0)

12 (63.2)

Positive

0 (0.0)

1 (50.0)

0 (0.0)

3 (42.9)

3 (75.0)

7 (36.8)

Negative

-

1 (50.0)

2 (40.0)

4 (57.1)

2 (50.0)

10 (52.6)

Positive

-

1 (50.0)

3 (60.0)

3 (42.9)

2 (50.0)

9 (47.4)

Variables

p53

Ki-67

sTn

sLea

sLex
Negative

0 (0.0)

0 (0.0)

1 (20.0)

1 (16.7)

2 (50.0)

4 (22.2)

Positive

1 (100.0)

2 (100.0)

4 (80.0)

5 (83.3)

2 (50.0)

14 (77.8)

PUNLMP: Papillary Urothelial Neoplasm of Low Malignant Potential.
UCC: Urothelial Cell Carcinoma.
SCC: Squamous Cell Carcinoma.
doi:10.1371/journal.pntd.0003329.t002

when compared to the other groups comprehending more
aggressive lesions presenting either invasion and/or high potential to invade the bladder wall (UCC, SCC, SCC+UC;
approximately 50% of the cases) (Table 2). Contrasting with
these findings, the percentage of proliferative phenotypes in the
less aggressive non-schistosome associated lesions (low grade
papillary tumours) was 30%. The percentage of proliferative
phenotypes in more aggressive high grade lesions, including high
grade urothelial cell and squamous cell carcinomas, was similar to
described for S. haematobium infection related lesions. The sLea
antigen was detected in approximately 50% of the S. haematobium-associated malignant lesions, irrespectively of their histology. These observations contrasted with the significantly higher
expression of sLea observed in lesions not associated with the
parasite (80% of the cases). Regarding the sTn antigen, its
frequency varies among the histological groups of tumours,
papilloma and UCC did not express the antigen, PUNLMP and
SCC showed an equal distribution of negative and positive cases.
However, the antigen was expressed by 75% of the cases
presenting both an UCC and SCC phenotype, which is in
accordance with our previous results for non-schistosome
associated bladder tumors, where sTn antigen was present in
approximately 75% of aggressive bladder tumors (high grade
papillary tumors and muscle invasive bladder cancer) [31].
Altogether, the studied biomarkers, with the exception of sLea
presented similar expressions in both schistosome and nonschistosome associated bladder tumors.
Benign/pre-malignant lesions associated with S. haematobium
infection, irrespective of having been isolated from urothelium
without malignant lesions or tumour adjacent mucosa, were also
studied (Fig. 1). The p53 protein was altered in the majority of the
benign/pre-malignant lesions (88%), predominantly in those
showing cellular alterations (urothelial hyperplasia, epidermoid
metaplasia, dysplasia; Table 3). Approximately 40% of the cases
also presented a high proliferation index (Ki-67.17%), although
PLOS Neglected Tropical Diseases | www.plosntds.org

this was more pronounced among epidermoid metaplasia (64.3%,
Table 3). The sTn antigen was detected in one third of the lesions
(32.6%), however it was mainly absent in chronic inflammation
cases and when compared with all the others a trend association
was observed (P = 0.067). The sialylated Lewis antigens sLea and
sLex were detected in the majority of the cases (.80%). However,
the percentage of sLea positive cases was higher among the cases
with urothelial hyperplasia while sLex was present in all dysplasia
cases (4/4; Table 3). Furthermore, none of the normal urothelium
tissues were positive for the studied biomarkers, demonstrating its
cancer-associated nature.
Table 4 further highlights the relationship between the studied
markers in the benign/pre-malignant lesions identified in apparently normal bladder mucosa and those found in tumor adjacent
mucosa. The distribution of the p53 alterations, sTn and sLex
antigens overexpression was similar between the two groups.
However, a higher number of non-proliferative cases were
observed in sole benign/pre-malignant lesions when compared
with the lesions in tumour adjacent mucosa (73.9% vs 42.1%,
P = 0.037; Table 4). On the other hand, sLea expression was more
frequent in lesions without tumour than with concomitant tumours
(91.7% vs 66.7%; P = 0.03). Altogether this data shows that the
majority of the benign/pre-malignant lesions associated with S.
haematobium infection share alterations in p53 expression and sLex
with bladder tumors. The predominance of sLea in pre-malignant
lesions, in particular in bladders that do not present signs of
malignant transformation, suggesting that this glycan may be a
molecular alteration associated with early carcinogenesis pathways.
Table 5 further shows the correlation between the expression of
the biomarkers in the tumours and adjacent mucosa lesions. This
showed a correlation between the expression of p53, sTn, sLea and
sLex both in the lesion and tumour, denoting that the tumour
adjacent mucosa reflects the molecular alterations found in S.
haematobium-associated tumours.
5
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Table 3. Cancer associated markers expression in benign/pre-malignant lesions.

Chronic Inflammation

Urothelial Hyperplasia

Epidermoid
Metaplasia

Dysplasia

Total

n (%)

n (%)

n (%)

n(%)

n (%)

Negative

3 (25.0)

1 (7.7)

1 (7.7)

0 (0.0)

5 (11.9)

Positive (altered)

9 (75.0)

12 (92.3)

12 (92.3)

4 (100.0)

37 (88.1)

Variables

p53

Ki-67
Non proliferative

6 (54.5)

11 (84.6)

5 (35.7)

3 (75.0)

25 (59.5)

Proliferative (.17%)

5 (45.5)

2 (15.4)

9 (64.3)

1 (25.0)

17 (40.5)

Negative

11(91.7)

8 (61.5)

8 (57.1)

2 (50.0)

29 (67.4)

Positive

1 (8.3)

5 (38.5)

6 (42.9)

2 (50.0)

14 (32.6)

Negative

4 (33.3)

1 (7.7)

3 (21.4)

1 (25.0)

8 (19.0)

Positive

8 (67.7)

12 (92.3)

11 (78.6)

3 (75.0)

34 (81.0)

Negative

3 (25.0)

2 (15.4)

3 (21.4)

0 (0.0)

8 (18.6)

Positive

12 (75.0)

11 (84.6)

11 (78.6)

4 (100.0)

35 (81.4)

sTn

sLe

a

sLex

doi:10.1371/journal.pntd.0003329.t003

Moreover, it was observed that 60% of the cases presented S.
haematobium eggs embedded in the bladder urothelium, predominantly in benign/pre-malignant lesions without the presence of
tumour (75% vs 45%). However, no associations were found
between the expression of the studied markers and the presence
and absence of the eggs in the bladder at the time of diagnosis.
Altogether, these findings suggest that the presence of eggs in the

bladder may be an early event leading to carcinogenesis. Whether
the disorganization of the tissue associated with malignant
transformation may favor their release into the environment,
therefore explaining is lower presence in malignant tissues and
consequently the lack of correlation with the studied biomarkers,
warrants further investigation. It was further observed that the
majority of the cases (.75%) presented sLea and sLea positive eggs

Table 4. Relation between cancer associated markers in benign/pre-malignant lesions as sole lesions and in tumour adjacent
mucosa.

Variables

Benign/Pre-malignant
As sole lesion

In tumour adjacent mucosa

n (%)

n (%)

p*

p53
Negative

1 (4.2)

4 (22.2)

Positive (altered)

23 (95.8)

14 (77.8)

Non proliferative

17 (73.9)

8 (42.1)

Proliferative (.17%)

6 (26.1)

11 (57.9)

Negative

15 (62.5)

14 (73.7)

Positive

9 (37.5)

5 (26.3)

0.146

Ki-67

0.037

sTn

0.437

sLea
Negative

2 (8.3)

7 (36.8)

Positive

22 (91.7)

12 (63.2)

0.030

sLex
Negative

4 (16.7)

4 (21.1)

Positive

20 (83.3)

15 (78.9)

0.714

*

: Chi-square test;
doi:10.1371/journal.pntd.0003329.t004
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0,512

0,002

0,171

0,679
0,140
sLex

doi:10.1371/journal.pntd.0003329.t005

0,048
0,471

0,000
0,950

0,486
0,175

0,015
0,912

0,346

In contrast to the extensive cytogenetic and molecular
signatures existing for urothelial cell carcinoma, mainly found in
western populations, little is known about the molecular alterations
underlying the development of S. haematobium-associated bladder
cancer. Nevertheless, such information is pivotal to support a
definitive association between schistosomiasis and bladder cancer
development that, until now, has been mostly supported by
epidemiological studies. Furthermore, it may provide means for an
early identification of infected populations at a risk of developing
bladder cancer, which is a particular critical matter since the
majority of the cases are detected at a late stage due the absence of
appropriate medical facilities.
Herein we have screened a series of schistosome-associated
bladder tumours, their adjacent mucosa and also biopsies of
apparently normal urothelia, for bladder cancer biomarkers. We
also included a series of bladder tumours of non-schistosome
etiology and normal urothelium sections in an attempt to highlight
common molecular alterations. The majority of the patients
enrolled in this study were females, and this is in clear contrast
with the higher prevalence of bladder cancer among men in
western populations. This may be explained by social and working
habits of these populations living in the proximity of contaminated
water courses. Also, the majority of the cases of bladder cancer
were observed among young adults, which is rare for urothelial
carcinomas of chemical etiology [40]. These findings were in
accordance with previous observations from other authors [5,8]
and support a role for the parasite in cancer development.
The evaluated biomarkers included the accumulation of
oncoprotein p53 [22–24] and tumour proliferation index given
by Ki-67 overexpression [26–28], two events associated with the
aggressiveness of urothelial bladder cancer. Likewise, we observed
alterations in p53 in the majority of schistosome-associated
bladder tumours, irrespectively of their histopathological nature,
which is in agreement with our findings and previous observations
for non-schistosome associated tumours [25,41]. In addition, these
alterations were not observable in the normal urothelium,
denoting its cancer-related nature. The association between the
accumulation of p53 in the urothelium and infection with S.
haematobium reinforces the notion that the parasite may contribute to profound alterations in urothelial cells, ultimately leading to
aggressive forms of cancer. This hypothesis is further supported by
the observations reported by Botelho and colleagues [8,19].
According to these authors, the exposure to S. haematobium
antigens down-regulates cell apoptotic pathways, which would
ultimately lead to the development of cancer [42]. Regarding
proliferation, Ki-67 overexpression was lower in low malignant
potential lesions when compared to urothelial and squamous cell
carcinomas. This is in accordance with previous findings
associating the degree of severity of bladder malignant lesions
with higher proliferation degrees and potential to evolve to more
aggressive forms of cancer [26,31]. Since several markers were
evaluated and a large numbers of comparisons were performed,
the false discovery rate should be considered. Nevertheless, if all

–0,027

–0,236

Discussion

0,556

0,016
sLea

0,945

and approximately half displayed eggs expressing the sTn antigen,
suggesting some degree of mimicry of host glycosylation patterns
(Fig. 2). The expression of sialylated glycans was validated by
observing the loss of reactivity against anti-glycans monoclonal
antibodies after treatment of the tissue with a neuraminidase. It
was noteworthy that both positive and negative eggs for these
antigens could be found within the same biopsy, denoting some
degree of heterogeneity at this level.

1,000

0,014

0,250
0,286
0,128
0,372
0,049
0,457
0,171
–0,378
–0,031
sTn

0,898

0,174

–0,570
0,078
–0,426
0,918
0,025
0,106
0,382
0,811
-0,057
Ki-67

Correlation Coefficient P value

0,346
0,901

Correlation Coefficient P value

0,033
0,896

Correlation Coefficient P value

0,033
0,814

Correlation Coefficient P value

–0,060
0,036

Correlation coefficient P value

0,484
p53

sLex
sLea
sTn
Ki-67
p53
Benign/Pre-malignant
Lesions

Bladder Cancer

Table 5. Correlation between cancer associated marker expression in the lesions and in the concomitant tumour.
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Fig. 2. Expression of cancer-associated glycans antigens A) sTn, B)sLea and C-D) sLex in Schistosoma haematobium eggs. The white
arrows point to positive eggs. The treatment of the tissue sections with a a-neuraminidase led to the loss of immunoreactivity, confirming the
validating the structural assignment.
doi:10.1371/journal.pntd.0003329.g002

the null hypotheses are true, 5% of the comparisons are expected
to present uncorrected P values lower than 0.05 by chance alone.
However, our study present P values under 0.05 in 20% of the
comparisons, thereby demonstrating the statistic value of the
observations.
The expression of cancer-associated cell-surface sialylated
glycans sTn, sLea and sLex was addressed, to our knowledge, for
the first time in S. haematobium-associated bladder tumours.
Glycosylation is the main and more complex posttranslational
modification of membrane-bound and secreted proteins. Glycans
plays a key role in protein folding and stability [43], mediate
several physiological and pathological conditions, which include
cell-cell adhesion, host-pathogen interactions, cell differentiation,
migration and cell trafficking, signaling and immune recognition
[44,45]. During malignant transformation, some cells change their
PLOS Neglected Tropical Diseases | www.plosntds.org

glycosylation profile in response to microenvironment challenge,
namely paracrine signaling, hypoxia among other events [29]. The
sTn antigen, resulting from a premature stop in the Oglycosylation of proteins by sialylation, has been found associated
with high-grade bladder non-muscle invasive papillary tumours
and muscle invasive lesions [30,31]. It has been found to enhance
bladder cancer cells capability to invade and migrate [31] and acts
as a suppressor of effective dendritic cell immune responses against
bladder cancer cells [46]. Despite the low number of cases, this
study suggests that the sTn antigen is predominantly expressed by
more aggressive forms of S. haematiobum associated tumours
(UCC+SCC). These observations are in accordance with our
previous results from non-schistosome associated bladder tumors,
were sTn expression is predominant found in high grade papillary
tumors and muscle invasive bladder cancer of non-schistosome
8
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etiology [31]. The sialylated Lewis blood group determinants sLea
and sLex may be found as terminal structures of both proteins and
lipids and have been associated with metastatic potential and poor
overall survival in several solid tumours [47–50]. The sLea antigen
has also been found both in pre-malignant bladder lesions, noninvasive and invasive bladder urothelial carcinomas [32–34];
however no association with recurrence, invasion or metastasis has
been reported. On the other hand, its structural isomer sLex
antigen was observed in muscle invasive urothelial carcinomas
associated with invasion, metastasis and recurrence [35,36]. This
study now demonstrates that the majority of schistosomeassociated bladder tumours expressed the sLex antigen, suggesting
a high degree of malignant potential. However, no defined
expression pattern could be drawn for sLea Similarly, we also
found significant overexpression of the sLex antigen in nonschistosome associated tumours but also a more pronounced
expression of sLea. However, none of these antigens were not
observed in the healthy urothelium, reinforcing its malignant
nature.
The analysis of benign/pre-malignant lesions, irrespectively of
their origin, showed a predominance of p53, sLea and sLex positive
cases. Noteworthy, sole lesions were predominantly non-proliferative when compared to lesions in the vicinity of tumours,
suggesting that high proliferation may be mainly a characteristic of
the tumour. Whether proliferative benign/pre-malignant lesions
present a higher risk of evolving to bladder cancer warrants
validation in future studies.
On the other hand, the sLea antigen was predominantly
expressed among sole lesions, denoting this antigen may constitute
a marker of early bladder carcinogenesis mediated by S.
haematobium. Reinforcing this observations, Kajiwara et al. has
described that sLea is inversely associated with the grade of atypia
while its non-sialylated form DU-PAN-2 correlates with the grade
of atypia in urothelial carcinomas; these authors also observed that
the disappearance of sLea and the presence of DU-PAN-2
correlates with high malignant potential [36]. We further observed
that the expression of cancer-associated antigens in the tumour
was correlated with the expression denoting a field effect that
affects the entire bladder. Again, this correlation was not observed
for proliferation, reinforcing this event see ms to be mainly a
characteristic of malignant lesions. Taken together, these observations highlight that pre-malignant lesions present molecular
alterations associated with malignancy, and that p53 and sLex are
surrogate markers of bladder cancerization associated with
infection with schistosomes. More studies should be conducted
to validate the potential of sLea has a surrogate marker of infection
that may be helpful in the monitoring of asymptomatic
colonization. A glycoproteomic/lipidomic characterization of
bladder tumours is ongoing, which is expected to provide their
necessary insights about the biologic role of the studied glycans in
bladder cancer.
These observations are also likely to be of consequence in the
clinic of great importance since benign and pre-malignant
lesions such as those included in this study are challenging to
diagnose by cystoscopy. We emphasize the potential of glycans
in context, as they can be found at the cell-surface, thus easily
accessible to antibodies and other carbohydrate ligands and
consequently be explored in cancer detection imaging [51,52].
They are often secreted into the blood stream and urine and
therefore readily accessible in non-invasive diagnosis [34,37,
38,53]. Non-invasive diagnostic procedures are critical as they
facilitate large scale screening of the populations in endemic
regions where imaging/radiological facilities are not likely to be
available.
PLOS Neglected Tropical Diseases | www.plosntds.org

Glycans are also important mediators in the colonization of
humans by parasites, as they provide means for efficient adhesion
and immune escape [54,55]. As such, we have also addressed the
expression of cancer-associated glycans in eggs of S. haematobium
embedded in the bladders. We observed, for the first time, that the
parasite eggs express sLea and sLex antigens, in mimicry of human
leukocytes. These glycans are specific ligands for E-selectin, a cell
adhesion molecule expressed only on endothelial cells and
activated by cytokines, such as IL-1 and TNF-a, released by
damaged cells during the course of inflammation [56,57].
Cytokines induce the overexpression of E-selectin by endothelial
cells on nearby blood vessels that are responsible for recruiting
leukocytes in a sLea/sLex-mediated manner [56,57]. These
glycans bind weakly to E-selectin which allows leukocytes to
‘‘roll’’ along the internal surface of the blood vessel into the injury
site by shear forces of blood flow [58]. Similar events may drive the
recruitment of S. haematobium eggs to the bladder wall, a critical
step in the developmental cycle of this pathogen. Similar strategies
have been observed in nature, namely by the Gram-negative
Porphyromonas gingivalis to adhere to human umbilical vein
endothelial cells [59]. Several authors have also hypothesized that
E-selectin-sialylated glycans interactions may contribute to the
hematogenous dissemination of sLea/sLex expressing tumour cells
and explain its association with metastasis [29,47,49,60]. Similarly,
for bladder tumors, the identification of the parasite glycoproteins
and/or glycolipids presenting these alterations may bring insights
on this matter and ultimately contribute to design strategies to
control infection. In addition, the identification of the glycoproteins and/or glycolipids presenting these alterations may yield
insights into this infection-associated cancer and ultimately
contribute to design strategies to control infection. Glycoproteomic
studies will greatly benefit from the recent mapping of the parasite
genome [61]. We further report that some eggs express the sTn
antigen, an oncofetal antigen that, we and others have shown to
play a key role in immune escape [46]. The sLex expression has
also been found to reduce the susceptibility of tumour cells to
hepatic sinusoidal lymphocyte-mediated killing, and thus, may
facilitate the ability of the tumor cells to metastasize to the liver
[62]. Similarly, the expression of these glycans by S. haematobium
may provide the necessary means for immune escape either by
modulation of the immune system or by molecular mimicry of the
host, a common survival strategy among parasites [63,64].
To conclude p53 and sialylated Lewis blood group determinants
may be surrogate markers of cancerization associated with chronic
infection with S. haematobium. By drawing attention to common
molecular pathways underlying these two events, this study
provides one of the missing links associating parasite infection
and cancer development. Further studies which include a larger
sample of Schistosoma haematobium positive cases will be needed
to determine a panel of biomarkers with the potential to identify
bladder cancer precursor lesions Finally, this report provides
insights on the glycosylation patterns of S. haematobium eggs and
discusses a possible model for the recruitment of eggs to the
bladder wall that suggests this schistosome has evolved glycosylation patterns that mimic those of its human host. These insights
may help guiding the development of novel therapeutic strategy,
namely glycoconjugate vaccines.
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